BioSpace

Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal

Investors looking for more transformative business development at Novo will have to wait, but a new partnership with China’s Hengrui Pharma adds a new weekly oral option to the Danish pharma’s early pipeline.

By BioSpace

1 min read
Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal
Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights